Zhang Jianchu, Deng Li, Xiong Xianzhi, Wang Pei, Xin Jianbao, Ma Wanli
Department of Respiratory Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
J Huazhong Univ Sci Technolog Med Sci. 2011 Aug;31(4):463. doi: 10.1007/s11596-011-0474-4. Epub 2011 Aug 7.
The expression of CD(8) (+)CD(25) (+)FoxP(3) (+) regulatory T cells (CD(8) (+)Tregs) in the peripheral blood of patients with stable chronic obstructive pulmonary disease (COPD), and the effect of muscarinic cholinergic receptor antagonist tiotropium bromide on the expression of CD(8) (+)Tregs were investigated. Twenty-three patients with moderate to severe stable COPD were enrolled in this study. All patients inhaled tiotropium bromide (18 μg daily) for 3 months. Before and after inhalation of tiotropium bromide, peripheral blood samples were collected from the patients, and T cells were labeled by three-color labeled monoclonal antibodies. Flow cytometry was used to detect the quantity and percentage of CD(8) (+)T cells, CD(8) (+)CD(25) (+)T cells, CD(8) (+)Tregs, CD(4) (+)T cells, CD(4) (+)CD(25) (+)T cells and CD(4) (+)CD(25) (+)FoxP(3) (+) regulatory T cells (CD(4) (+)Tregs) respectively. The percentage of CD(4) (+)T cells was increased from (27.82±2.18)% to (35.53±1.3)% (t=3.20, P=0.004) in the peripheral blood of patients with stable COPD after inhalation of tiotropium bromide for 3 months, that of CD(4) (+)CD(25) (+)T cells was decreased from (10.03 ±1.42)% to (4.21 ±0.65)% (t=3.78, P=0.001), and that of CD(8) (+)Tregs was increased from (8.41 ±1.68)% to (21.34 ±4.20)% (t=2.72, P=0.013). At baseline, CD(8) (+)T cells, CD(8) (+)CD(25) (+)T cells and CD(4) (+)Tregs were detectable in the peripheral blood, but no significant changes were observed after treatment. Linear correlation analysis revealed that the difference before and after treatment in CD(4) (+)T cells and CD(4) (+)CD(25) (+)T cells was negatively correlated with the ratio of change in CD(8) (+)Tregs before and after treatment (r=-0.61, P=0.013; r=-0.72, P=0.001 respectively). In the peripheral blood of patients with stable COPD, there was the expression of CD(8) (+)Tregs and CD(4) (+)Tregs. Muscarinic receptor antagonist, tiotropium bromide, can promote the amplification of CD(4) (+)T cells, inhibit the expression of CD(25) (+)T cells, and enhance the expression of CD(8) (+)Tregs. CD(8) (+)Tregs and CD(4) (+)Tregs can be used as new indicators to understand the immune status of patients. They are helpful in judging the treatment efficacy and disease immunophenotype.
研究稳定期慢性阻塞性肺疾病（COPD）患者外周血中CD(8)(+)CD(25)(+)FoxP(3)(+)调节性T细胞（CD(8)(+)Tregs）的表达情况，以及毒蕈碱胆碱能受体拮抗剂噻托溴铵对CD(8)(+)Tregs表达的影响。本研究纳入23例中度至重度稳定期COPD患者。所有患者吸入噻托溴铵（每日18μg），共3个月。在吸入噻托溴铵前后，采集患者外周血样本，并用三色标记单克隆抗体标记T细胞。采用流式细胞术分别检测CD(8)(+)T细胞、CD(8)(+)CD(25)(+)T细胞、CD(8)(+)Tregs、CD(4)(+)T细胞、CD(4)(+)CD(25)(+)T细胞和CD(4)(+)CD(25)(+)FoxP(3)(+)调节性T细胞（CD(4)(+)Tregs）的数量和百分比。吸入噻托溴铵3个月后，稳定期COPD患者外周血中CD(4)(+)T细胞百分比从(27.82±2.18)%增至(35.53±1.3)%（t=3.20，P=0.004），CD(4)(+)CD(25)(+)T细胞百分比从(10.03±1.42)%降至(4.21±0.65)%（t=3.78，P=0.001），CD(8)(+)Tregs百分比从(8.41±1.68)%增至(21.34±4.20)%（t=2.72，P=0.013）。基线时，外周血中可检测到CD(8)(+)T细胞、CD(8)(+)CD(25)(+)T细胞和CD(4)(+)Tregs，但治疗后未观察到明显变化。线性相关分析显示，治疗前后CD(4)(+)T细胞和CD(4)(+)CD(25)(+)T细胞的差异与治疗前后CD(8)(+)Tregs的变化比值呈负相关（r=-0.61，P=0.013；r=-0.72，P=0.001）。在稳定期COPD患者外周血中，存在CD(8)(+)Tregs和CD(4)(+)Tregs的表达。毒蕈碱受体拮抗剂噻托溴铵可促进CD(4)(+)T细胞扩增，抑制CD(25)(+)T细胞表达，并增强CD(8)(+)Tregs的表达。CD(8)(+)Tregs和CD(4)(+)Tregs可作为了解患者免疫状态的新指标。它们有助于判断治疗效果和疾病免疫表型。
